Carson-B (01167) subsidiary entered into a licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

The latest news released by the Wisdom Finance APP states that Jasco-B (01167) has announced that its non-wholly owned subsidiary Beijing Jasco New Drug R&D Co., Ltd. has entered into a licensing and cooperation agreement with AstraZeneca AB to develop and commercialize the pan-KRAS inhibitor JAB-23E73.